Management of Refractory Ascites
Refractory ascites should be managed primarily with serial large-volume paracentesis (LVP) with albumin replacement, and well-selected patients should be referred for transjugular intrahepatic portosystemic shunt (TIPS) placement. 1
Primary Treatment Approach
The cornerstone of refractory ascites management is therapeutic paracentesis performed as frequently as needed based on symptom recurrence 1. This represents the most practical and immediately available intervention for most patients.
Albumin Replacement Protocol
When performing LVP:
- For volumes >5 L removed: Administer 20-25% intravenous albumin at 6-8 g per liter removed 1
- For smaller volumes: Consider albumin if the patient has hypotension, renal insufficiency, or electrolyte abnormalities 1
- This prevents post-paracentesis circulatory dysfunction, which is associated with worse outcomes 2
Diuretic Management in Refractory Ascites
Once refractoriness is confirmed, diuretics should generally be discontinued 2. The exception is when renal sodium excretion on diuretics exceeds 30 mmol/day—in these cases, maintenance diuretic therapy can be considered if tolerated 2. This nuance is important because continuing ineffective diuretics only increases the risk of electrolyte disturbances and renal impairment without benefit.
TIPS as Definitive Therapy
Well-selected patients with refractory ascites should be referred for TIPS evaluation 1. TIPS can eliminate ascites entirely and represents the most effective non-transplant intervention. However, patient selection is critical:
TIPS Considerations
- Requires careful cardiac evaluation to exclude contraindications
- Risk of hepatic encephalopathy (consider prophylactic rifaximin starting pre-TIPS) 3
- Under-dilating the TIPS at insertion may reduce complications 3
- Not suitable for patients with cardiac dysfunction or severe hepatic encephalopathy
Liver Transplantation Evaluation
All patients with refractory ascites should be immediately evaluated for liver transplantation if not already listed 2. Refractory ascites carries a median survival of approximately 6 months 2, making this a critical decompensation event that warrants urgent transplant consideration. Standard prognostic scores may underestimate mortality risk in these patients 2.
Emerging and Alternative Therapies
For patients ineligible for TIPS or awaiting transplantation:
- Alfapump: FDA-approved in 2024 for refractory ascites, reduces need for LVP but carries risks of renal impairment and infection requiring antibiotic prophylaxis 4
- Long-term albumin infusions: May delay onset of refractoriness and improve survival when started early 3
Critical Pitfalls to Avoid
Do not continue high-dose diuretics once refractoriness is established—this only causes harm through electrolyte derangements and renal injury 2
Avoid NSAIDs, ACE inhibitors, angiotensin II antagonists, and alpha-blockers in patients with ascites due to increased risk of renal impairment 2
Do not delay transplant evaluation—the poor prognosis demands immediate referral 2
Ensure diagnostic paracentesis is performed to exclude spontaneous bacterial peritonitis before attributing worsening ascites to refractoriness alone 1
Algorithmic Approach
Confirm true refractoriness: Patient on maximum diuretics (spironolactone 400 mg/day + furosemide 160 mg/day) with sodium restriction <90 mmol/day for at least 1 week, with weight loss <0.8 kg over 4 days 2
Discontinue or reduce diuretics (unless sodium excretion >30 mmol/day) 2
Initiate serial LVP with albumin as primary management 1
Simultaneously evaluate for TIPS if patient is appropriate candidate 1
Refer for liver transplantation evaluation immediately 2
Consider alfapump for TIPS-ineligible patients with frequent paracentesis needs 4
The most recent 2025 AGA guidelines 1 align closely with the 2018 EASL guidelines 2, providing consistent evidence-based direction that LVP with albumin and TIPS referral form the therapeutic backbone for refractory ascites management.